Table 1.

Response criteria evaluating glioblastoma progression

Response Criteria	Extent of Response
	Complete Response	Partial Response	Stable Disease	Progression
Response Evaluation Criteria In Solid Tumours (RECIST)24	No enhancing disease for 4 weeks	≥50% decrease in enhancing lesion size and no new lesions	Does not qualify as any other Extent of Response	≥25% increase in enhancing lesion size or any new lesion
MacDonald Criteria34	No enhancing disease for 4 weeks, no corticosteroid, and neurologically stable or improved	≥50% decrease in enhancing lesion size, no new lesions, and stable or improved clinically	Does not qualify as any other Extent of Response	≥25% increase in enhancing lesion size, any new lesion, or clinical deterioration related to disease progression
Response Assessment in Neuro- Oncology Working Group (RANO)7	No enhancing disease for 4 weeks*, stable or improved T2/ FLAIR lesions, no corticosteroid, and neurologically stable or improved	≥50% decrease in enhancing lesion size, stable or improved T2/ FLAIR lesions, no new lesions, and stable or improved clinically	Does not qualify as any other Extent of Response	≥25% increase in enhancing lesion size, increasing T2/FLAIR lesion size, any new lesion**, or clinical deterioration related to disease progression

* Patients with non-measurable disease cannot be described as having a complete response

** New lesions outside of the radiation field are not considered to be secondary to pseudoprogression